Dexmedetomidine supplemented analgesia for delirium and prolong survival after surgrey

Not Applicable

• Conditions: Postoperative patients

• Registration Number: JPRN-jRCTs021200016
• Lead Sponsor: Hirota Kazuyoshi

Brief Summary

one

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-08-13
• Study Completion: 2022-05-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 0

Inclusion Criteria

1 Age older than 65 years, less than 90 years
2 Scheduled to undergo surgery for primary solid organ cancer under general anesthesia, with an expected duration of surgery longer than 2 hours
3 Planned to use patient-controlled intravenous analgesia (PCIA) after surgery
4 Provide written informed consent.

Exclusion Criteria

Patients who meet any of the following criteria will be excluded.
1 Preoperative history of schizophrenia, epilepsy, Parkinsonism, or myasthenia gravis;
2 Preoperative radio- or chemotherapy;
3 Inability to communicate in the preoperative period because of coma, profound dementia or language barrier;
4 Preoperative obstructive sleep apnea (previously diagnosed as obstructive sleep apnea, or STOP-Bang scoring model score
5 Brain injury or neurosurgery;
6 Preoperative left ventricular ejection fraction < 30%, sick sinus syndrome, severe sinus bradycardia (< 50 beats per minute), or second-degree or above atrioventricular block without pacemaker;
7 Severe hepatic dysfunction (Child-Pugh class C) or severe renal dysfunction (requirement of renal replacement therapy before surgery);
8 ASA classification IV or above.

Study & Design

• Study Type: Interventional
• Study Design: Not specified